Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131


Interferon-β corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection.

Feng X, Bao R, Li L, Deisenhammer F, Arnason BGW, Reder AT.

EBioMedicine. 2019 Nov;49:269-283. doi: 10.1016/j.ebiom.2019.09.059. Epub 2019 Oct 21.


Vitamin D enhances responses to interferon-β in MS.

Feng X, Wang Z, Howlett-Prieto Q, Einhorn N, Causevic S, Reder AT.

Neurol Neuroimmunol Neuroinflamm. 2019 Oct 3;6(6):e622. doi: 10.1212/NXI.0000000000000622. Print 2019 Nov.


Dimethyl fumarate-induced changes in the MS lymphocyte repertoire: No need for subset monitoring.

Killestein J, Reder AT.

Neurology. 2019 Apr 9;92(15):696-697. doi: 10.1212/WNL.0000000000007255. Epub 2019 Mar 27. No abstract available.


Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.

Koskimäki F, Bernard J, Yong J, Arndt N, Carroll T, Lee SK, Reder AT, Javed A.

PLoS One. 2018 Dec 21;13(12):e0209326. doi: 10.1371/journal.pone.0209326. eCollection 2018.


Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.

Goodin DS, Reder AT, Traboulsee AL, Li DK, Langdon D, Cutter G, Cook S, O'Donnell T, Kremenchutzky M, Oger J, Koelbach R, Pohl C, Wicklein EM; IFNB Multiple Sclerosis Study Group and the 16- and 21-Year LTF Investigators.

Mult Scler. 2019 May;25(6):837-847. doi: 10.1177/1352458518773511. Epub 2018 May 15.


Effective treatment of CLIPPERS with long-term use of rituximab.

Cipriani VP, Arndt N, Pytel P, Reder AT, Javed A.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e448. doi: 10.1212/NXI.0000000000000448. eCollection 2018 May. No abstract available.


Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy.

Daif A, Lukas RV, Issa NP, Javed A, VanHaerents S, Reder AT, Tao JX, Warnke P, Rose S, Towle VL, Wu S.

Epilepsy Behav. 2018 Mar;80:331-336. doi: 10.1016/j.yebeh.2018.01.021. Epub 2018 Feb 9. Review.


Vitamin D and Multiple Sclerosis: A Comprehensive Review.

Sintzel MB, Rametta M, Reder AT.

Neurol Ther. 2018 Jun;7(1):59-85. doi: 10.1007/s40120-017-0086-4. Epub 2017 Dec 14. Review.


Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon β-1a in the EVIDENCE study.

Coyle PK, Reder AT, Freedman MS, Fang J, Dangond F.

J Neurol Sci. 2017 Aug 15;379:151-156. doi: 10.1016/j.jns.2017.05.052. Epub 2017 May 25.


Corrigendum to 'Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature' [Mult. Scler. Relat. Disord. 9 (2016) 158-162].

Grebenciucova E, Reder AT, Bernard JT.

Mult Scler Relat Disord. 2016 Nov;10:213. doi: 10.1016/j.msard.2016.09.010. Epub 2016 Oct 6. No abstract available.


Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature.

Grebenciucova E, Reder AT, Bernard JT.

Mult Scler Relat Disord. 2016 Sep;9:158-62. doi: 10.1016/j.msard.2016.07.015. Epub 2016 Aug 4. Review. Erratum in: Mult Scler Relat Disord. 2016 Nov;10:213.


Relapses in multiple sclerosis: Relationship to disability.

Goodin DS, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, Lublin FD, Lucchinetti CF, Miller AE, Pelletier D, Racke MK, Trapp BD, Vartanian T, Waubant E.

Mult Scler Relat Disord. 2016 Mar;6:10-20. doi: 10.1016/j.msard.2015.09.002. Epub 2015 Sep 8. Review.


Rising JCV-Ab index during natalizumab therapy for MS: Inauspicious for a highly efficacious drug.

Javed A, Reder AT.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(1):e199. doi: 10.1212/NXI.0000000000000199. eCollection 2016 Feb. No abstract available.


The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis.

Hunter SF, Bowen JD, Reder AT.

CNS Drugs. 2016 Feb;30(2):135-47. doi: 10.1007/s40263-015-0297-0. Review.


Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.

Voskuhl RR, Wang H, Wu TC, Sicotte NL, Nakamura K, Kurth F, Itoh N, Bardens J, Bernard JT, Corboy JR, Cross AH, Dhib-Jalbut S, Ford CC, Frohman EM, Giesser B, Jacobs D, Kasper LH, Lynch S, Parry G, Racke MK, Reder AT, Rose J, Wingerchuk DM, MacKenzie-Graham AJ, Arnold DL, Tseng CH, Elashoff R.

Lancet Neurol. 2016 Jan;15(1):35-46. doi: 10.1016/S1474-4422(15)00322-1. Epub 2015 Nov 29.


First-dose effects of fingolimod: Pooled safety data from three phase 3 studies.

DiMarco JP, O'Connor P, Cohen JA, Reder AT, Zhang-Auberson L, Tang D, Collins W, Kappos L.

Mult Scler Relat Disord. 2014 Sep;3(5):629-38. doi: 10.1016/j.msard.2014.05.005. Epub 2014 Jun 17.


Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.

Poulos C, Kinter E, Yang JC, Bridges JF, Posner J, Reder AT.

Patient. 2016 Apr;9(2):171-80. doi: 10.1007/s40271-015-0136-x.


Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis.

Reder AT, Oger JF, Kappos L, O'Connor P, Rametta M.

Mult Scler Relat Disord. 2014 May;3(3):294-302. doi: 10.1016/j.msard.2013.11.005. Epub 2013 Nov 26. Review.


Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.

Arvin AM, Wolinsky JS, Kappos L, Morris MI, Reder AT, Tornatore C, Gershon A, Gershon M, Levin MJ, Bezuidenhoudt M, Putzki N.

JAMA Neurol. 2015 Jan;72(1):31-9. doi: 10.1001/jamaneurol.2014.3065.


Immunomodulatory activity of interferon-beta.

Kasper LH, Reder AT.

Ann Clin Transl Neurol. 2014 Aug;1(8):622-31. doi: 10.1002/acn3.84. Epub 2014 Jul 23. Review.


Induction of a unique isoform of the NCOA7 oxidation resistance gene by interferon β-1b.

Yu L, Croze E, Yamaguchi KD, Tran T, Reder AT, Litvak V, Volkert MR.

J Interferon Cytokine Res. 2015 Mar;35(3):186-99. doi: 10.1089/jir.2014.0115. Epub 2014 Oct 20.


How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms.

Reder AT, Feng X.

J Interferon Cytokine Res. 2014 Aug;34(8):589-99. doi: 10.1089/jir.2013.0158. Review.


Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.

Lancet Neurol. 2014 Jun;13(6):545-56. doi: 10.1016/S1474-4422(14)70049-3. Epub 2014 Mar 28. Erratum in: Lancet Neurol. 2013 Jun;13(6):536.


Validity of the Neurology Quality-of-Life (Neuro-QoL) measurement system in adult epilepsy.

Victorson D, Cavazos JE, Holmes GL, Reder AT, Wojna V, Nowinski C, Miller D, Buono S, Mueller A, Moy C, Cella D.

Epilepsy Behav. 2014 Feb;31:77-84. doi: 10.1016/j.yebeh.2013.11.008. Epub 2013 Dec 20.


Genetic variation near IRF8 is associated with serologic and cytokine profiles in systemic lupus erythematosus and multiple sclerosis.

Chrabot BS, Kariuki SN, Zervou MI, Feng X, Arrington J, Jolly M, Boumpas DT, Reder AT, Goulielmos GN, Niewold TB.

Genes Immun. 2013 Dec;14(8):471-8. doi: 10.1038/gene.2013.42. Epub 2013 Aug 22.


Severe early bilateral macular edema following fingolimod therapy.

Coppes OJ, Gutierrez I, Reder AT, Ksiazek S, Bernard J.

Mult Scler Relat Disord. 2013 Jul;2(3):256-8. doi: 10.1016/j.msard.2012.11.004. Epub 2013 Jan 16.


Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.

Zarbin MA, Jampol LM, Jager RD, Reder AT, Francis G, Collins W, Tang D, Zhang X.

Ophthalmology. 2013 Jul;120(7):1432-9. doi: 10.1016/j.ophtha.2012.12.040. Epub 2013 Mar 24.


Cystoid macular edema associated with fingolimod use for multiple sclerosis.

Afshar AR, Fernandes JK, Patel RD, Ksiazek SM, Sheth VS, Reder AT, Hariprasad SM.

JAMA Ophthalmol. 2013 Jan;131(1):103-7. doi: 10.1001/jamaophthalmol.2013.570. No abstract available.


Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.

Goodin DS, Ebers GC, Cutter G, Cook SD, O'Donnell T, Reder AT, Kremenchutzky M, Oger J, Rametta M, Beckmann K, Knappertz V.

BMJ Open. 2012 Nov 30;2(6). pii: e001972. doi: 10.1136/bmjopen-2012-001972. Print 2012.


Response to GS Gronseth and E Ashman.

Goodin DS, Reder AT.

Mult Scler. 2012 Nov;18(11):1661-2; author reply 1663-4. doi: 10.1177/1352458512463484. No abstract available.


Treatment with interferon beta for multiple sclerosis.

Goodin DS, Reder AT, Cutter G.

JAMA. 2012 Oct 24;308(16):1627; author reply 1627-8. doi: 10.1001/jama.2012.13570. No abstract available.


Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins.

Feng X, Han D, Kilaru BK, Franek BS, Niewold TB, Reder AT.

Arch Neurol. 2012 Oct;69(10):1303-9.


Brief International Cognitive Assessment for MS (BICAMS): international standards for validation.

Benedict RH, Amato MP, Boringa J, Brochet B, Foley F, Fredrikson S, Hamalainen P, Hartung H, Krupp L, Penner I, Reder AT, Langdon D.

BMC Neurol. 2012 Jul 16;12:55. doi: 10.1186/1471-2377-12-55.


Evidence-based medicine: promise and pitfalls.

Goodin DS, Reder AT.

Mult Scler. 2012 Jul;18(7):947-8. doi: 10.1177/1352458512451660. No abstract available.


Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis.

Croze E, Yamaguchi KD, Knappertz V, Reder AT, Salamon H.

Pharmacogenomics J. 2013 Oct;13(5):443-51. doi: 10.1038/tpj.2012.27. Epub 2012 Jun 19.


Homonymous hemimacular thinning: a unique presentation of optic tract injury in neuromyelitis optica.

Romero RS, Gutierrez I, Wang E, Reder AT, Bhatti MT, Bernard JT, Javed A.

J Neuroophthalmol. 2012 Jun;32(2):150-3. doi: 10.1097/WNO.0b013e3182504688.


Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology.

Cella D, Lai JS, Nowinski CJ, Victorson D, Peterman A, Miller D, Bethoux F, Heinemann A, Rubin S, Cavazos JE, Reder AT, Sufit R, Simuni T, Holmes GL, Siderowf A, Wojna V, Bode R, McKinney N, Podrabsky T, Wortman K, Choi S, Gershon R, Rothrock N, Moy C.

Neurology. 2012 Jun 5;78(23):1860-7. doi: 10.1212/WNL.0b013e318258f744. Epub 2012 May 9.


Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.

Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, DeSimone TM, Knappertz V.

Neurology. 2012 Apr 24;78(17):1315-22. doi: 10.1212/WNL.0b013e3182535cf6. Epub 2012 Apr 11.


Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.

Goodin DS, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, Wolf C, Beckmann K, Konieczny A, Ebers GC; 16-Year Long Term Follow-up Study Investigators.

J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):282-7. doi: 10.1136/jnnp-2011-301178. Epub 2011 Dec 21.


Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS).

Langdon DW, Amato MP, Boringa J, Brochet B, Foley F, Fredrikson S, Hämäläinen P, Hartung HP, Krupp L, Penner IK, Reder AT, Benedict RH.

Mult Scler. 2012 Jun;18(6):891-8. doi: 10.1177/1352458511431076. Epub 2011 Dec 21. Review.


Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.

Patsopoulos NA; Bayer Pharma MS Genetics Working Group; Steering Committees of Studies Evaluating IFNβ-1b and a CCR1-Antagonist; ANZgene Consortium; GeneMSA; International Multiple Sclerosis Genetics Consortium, Esposito F, Reischl J, Lehr S, Bauer D, Heubach J, Sandbrink R, Pohl C, Edan G, Kappos L, Miller D, Montalbán J, Polman CH, Freedman MS, Hartung HP, Arnason BG, Comi G, Cook S, Filippi M, Goodin DS, Jeffery D, O'Connor P, Ebers GC, Langdon D, Reder AT, Traboulsee A, Zipp F, Schimrigk S, Hillert J, Bahlo M, Booth DR, Broadley S, Brown MA, Browning BL, Browning SR, Butzkueven H, Carroll WM, Chapman C, Foote SJ, Griffiths L, Kermode AG, Kilpatrick TJ, Lechner-Scott J, Marriott M, Mason D, Moscato P, Heard RN, Pender MP, Perreau VM, Perera D, Rubio JP, Scott RJ, Slee M, Stankovich J, Stewart GJ, Taylor BV, Tubridy N, Willoughby E, Wiley J, Matthews P, Boneschi FM, Compston A, Haines J, Hauser SL, McCauley J, Ivinson A, Oksenberg JR, Pericak-Vance M, Sawcer SJ, De Jager PL, Hafler DA, de Bakker PI.

Ann Neurol. 2011 Dec;70(6):897-912. doi: 10.1002/ana.22609. Erratum in: Ann Neurol. 2013 Apr;73(4):561.


Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS.

Goodin DS, Jones J, Li D, Traboulsee A, Reder AT, Beckmann K, Konieczny A, Knappertz V; 16-Year Long-Term Follow-up Study Investigators.

PLoS One. 2011;6(11):e22444. doi: 10.1371/journal.pone.0022444. Epub 2011 Nov 30.


Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis.

Feng X, Reder NP, Yanamandala M, Hill A, Franek BS, Niewold TB, Reder AT, Javed A.

J Neurol Sci. 2012 Feb 15;313(1-2):48-53. doi: 10.1016/j.jns.2011.09.032. Epub 2011 Oct 27.


Interferonβ-1b Induces the Expression of RGS1 a Negative Regulator of G-Protein Signaling.

Tran T, Paz P, Velichko S, Cifrese J, Belur P, Yamaguchi KD, Ku K, Mirshahpanah P, Reder AT, Croze E.

Int J Cell Biol. 2010;2010:529376. doi: 10.1155/2010/529376. Epub 2011 Jan 17.


Fingolimod for the treatment of relapsing multiple sclerosis.

Jeffery DR, Markowitz CE, Reder AT, Weinstock-Guttman B, Tobias K.

Expert Rev Neurother. 2011 Feb;11(2):165-83. doi: 10.1586/ern.10.193. Epub 2010 Dec 16. Review.


MxA: a biomarker for predicting multiple sclerosis disease activity.

Reder AT.

Neurology. 2010 Oct 5;75(14):1222-3. doi: 10.1212/WNL.0b013e3181f6466f. No abstract available.


Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.

Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS.

Lancet Neurol. 2010 Jul;9(7):740-50. doi: 10.1016/S1474-4422(10)70103-4.


Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.

Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, Bogumil T, Beckmann K, Wolf C, Konieczny A; Investigators of the 16-year Long-Term Follow-Up Study.

J Neurol Neurosurg Psychiatry. 2010 Aug;81(8):907-12. doi: 10.1136/jnnp.2009.204123. Epub 2010 Jun 19.


Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.

Reder AT, Ebers GC, Traboulsee A, Li D, Langdon D, Goodin DS, Bogumil T, Beckmann K, Konieczny A; Investigators of the 16-Year Long-Term Follow-Up Study.

Neurology. 2010 Jun 8;74(23):1877-85. doi: 10.1212/WNL.0b013e3181e240d0.


Supplemental Content

Loading ...
Support Center